CASE STUDY: USING MARKET FORCE TEMPLATE TO UNDERSTAND PHARMA RETAIL MARKETS IN FRANCE
|
|
- Dwight Anthony
- 6 years ago
- Views:
Transcription
1 CASE STUDY: USING MARKET FORCE TEMPLATE TO UNDERSTAND PHARMA RETAIL MARKETS IN FRANCE By April Harding BACKGROUND This case study presents examples of retail pharmacy markets to illustrate how to use the Market Force Template (MFT) to better understand market dynamics in two countries France and Nigeria. The first case Nigeria demonstrates how to use the MFT. The Group Work will use the France example as an exercise to learn how to use the MFT. NIGERIA RETAIL PHARMACY MARKET Private retail pharmacy market Many reports suggest that the private part of Nigeria s drug retail dispensing market approximates a full-on market. For the most part, the only forces governing actors behavior are market forces sellers are selling, buyers are buying and the interactions one observes are the result of buyers and sellers spontaneous choices (see Figure 1). There are rules on the books restricting the behavior of private drug sellers, but, by and large, their day-to-day behavior is not much influenced by those rules. France and Nigeria Retail Pharmacy Markets Page 1
2 Customer competition: Private dispensers and retailers rely completely on customers to choose their services and to secure their income. This places customer competition domain to the far right (=> full on market forces). Market price: Prices are set by market interactions sellers deciding what prices make sense, buyers deciding what they can afford. This places market prices domain to the far right (=> full on market forces). France and Nigeria Retail Pharmacy Markets Page 2
3 Market entry/exit: Certainly, there are formal entry barriers, but those rules are not much observed. This gap between formal rules and day-to-day practice underscores an important feature of the framework: it aims to reflect the actual market and structuring forces (and by inference the actual governance regime) in action. It does not portray the formal rules and mechanisms in place. So, if there are strict rules and requirements about opening a pharmacy, but they are generally not observed or followed, then we characterize the domain as having low barriers to entry, and therefore, being subjected strongly to market forces. This places market entry/exit domain to the far right (=> full on market forces). Financial autonomy: There is no social funding, that is, people pay private pharmacies privately. This places financial autonomy domain to the far right (=> full on market forces). Contract conditionality: Virtually no private pharmacies are included in networks with social/ public reimbursement. Hence, they need not meet performance criteria for network inclusion. Pharmacies feel very little performance pressure related to obtaining or being reimbursed under contracts. This places contract conditionality domain to the far right (=> full on market forces). Public retail pharmacy market However, the public sector also dispenses drugs (see Figure 2). Operational autonomy: Publicly-covered drugs are dispensed in public clinics. Therefore, drug-dispensing activities of public clinics are not run as France and Nigeria Retail Pharmacy Markets Page 3
4 businesses. Rather, public policies determine what drugs they stock, set opening hours, and specify staffing requirements, etc. They have little day-to-day operational autonomy. This places operational autonomy domain to the far left (<=full on stewardship forces). Customer competition: As there is little concern that patients may go elsewhere, staff are not driven by the pressure to compete for customers; this is low customer competition since customer choices don t influence clinic/pharmacy income, by and large. This places customer competition domain to the far left (<=full on stewardship forces). Market prices: Prices are set administratively which places public pharmacy services all the way to the left (no market forces) in the market prices domain. This places market prices domain to the far left (<=full on stewardship forces). Market entry/exit: An individual cannot open a public pharmacy and dispense subsidized drugs; so, entry barriers are high (no market forces). This places market entry/barrier domain to the far left (<=full on stewardship forces). Financial autonomy: Drugs dispensed in public clinics are heavily or completely subsidized, so this places financial autonomy to the far left (<=full on stewardship forces). Contract conditionality: There are no contracts there is no need for clinics to compete for eligibility to participate in a network, nor is there pressure to perform well to receive performance linked reimbursement under a contract. Placing these activities, again, all the way to the left (no market forces) on the under contracts domain. This places contract conditionality to the far left (<=full on stewardship forces). Total market system Figure 3 portray both parts of the market together within a single graphic. This illustrates a valuable feature of the framework - the ability to characterize both parts of a whole market, giving due attention to their interconnectedness, yet also, to their distinct governance regimes. France and Nigeria Retail Pharmacy Markets Page 4
5 For privately dispensed drugs, stewardship forces are all the way to the right in each domain, exhibiting very strong market forces, and very few structuring forces. The governance regime that is operating is very close to what is considered full-on or a completely unstructured, market. This full-on market governance regime generates drug dispensing services with certain qualities: services are widely available, exhibit uncertain quality, are costly, involve excessively-prescribed drugs, and are delivered with considerable responsiveness to customers with pleasant and respectful treatment. In the public part of the market, the no market forces or traditional public administration generates drug dispensing services with a slightly different set of qualities: services where drugs are often unavailable, are of more certain quality, are less financially costly to patients. In addition, these services typically exhibit less excessive prescribing, but dispensing drugs may be costly in terms of the time and the hassle involved. Further, patients are typically treated less pleasantly. In the operation of the retail pharmacy services market in Nigeria, there are signs that the government has chosen to supplant markets by deploying direct delivery as their main policy tool for pursuing their objectives France and Nigeria Retail Pharmacy Markets Page 5
6 to make essential medicines available and affordable. The government aims to deliver needed drugs to people through public clinics and public supply chains. Mechanisms to structure the interaction in the private marketized side of the sub-sector are functioning poorly, if at all. Perhaps, the government expects that peoples most important drug needs will soon be met on the public side, with the private and highly marketized part operating as a relatively minor residual element of the retail pharmacy market. Regardless, the outcome is that the majority of drug dispensing activity is taking place in an almost entirely pure market. France and Nigeria Retail Pharmacy Markets Page 6
7 GROUP WORK ACTIVITY Read the France Retail Pharmacy Market case study. Thinking about what you have read, please answer the following questions. Be prepared to share your analysis with the larger group. Use the Market Force Template to guide your analysis. 1. Please use the Market Forces Framework below to analyze what market forces are at play in the primary health care in France? 2. In what sense are market forces operating in French Retail Pharmacy Market? 3. Given the significant role of market forces, how does France achieve their policy and social goals in this market? What Tools of Governance(s) do they apply? Market Forces Template France and Nigeria Retail Pharmacy Markets Page 7
8 FRANCE RETAIL PHARMACY MARKET Subsidy domain: Like much of the French health system, market forces operate in the drug retail services market. Patients obtain prescribed drugs at pharmacies and pay for them out-of-pocket. Then, they are reimbursed for their payments. A commission (with representation from the Ministries of Health, Finance, and, Industry) regulates prices for covered, prescriptions medicines. Most are reimbursed at 65%, while some with a low medical benefit are reimbursed at much lower rates (e.g. 15%). All people receive these partial reimbursements for covered drugs, but some people are covered fully (e.g. poor people; people with high medical costs). In total, drug expenditures are approximately 60% public, 40% public. This produces moderately high structuring forces relative to market forces on the subsidy domain (approximately 1/3 of the way from no market forces / left side). Operational autonomy: Most pharmacies are private businesses (except for pharmacies within public hospitals). These pharmacies must follow rules on dispensing, hours, etc. but are relatively autonomous. Customer competition: Since customers are reimbursed for their out-of-pocket costs related to drugs, pharmacies compete for customers based on services. Market prices: Prices for covered drugs are set by negotiation. Market entry/exit: Pharmacists must belong to the professional body. And there are other entry barriers, such as retail pharmacy chains are prohibited. Contract conditionality: A pharmacy business cannot survive unless it meets and maintains the standards for operation required for social insurance reimbursement. When starting a business, an applicant makes considerable effort to demonstrate that s/he can meet these standards. The entry barrier for the contract agreement secures his/her eligibility and provides for reimbursements for the customers s/he serves. France and Nigeria Retail Pharmacy Markets Page 8
9 ANSWER France and Nigeria Retail Pharmacy Markets Page 9
MM H MANAGING MARKETS FOR HEALTH The World Bank Group in collaboration with the University of Edinburgh and ACCESS Health International October, 2015
MM H MANAGING MARKETS FOR HEALTH The World Bank Group in collaboration with the University of Edinburgh and ACCESS Health International October, 2015 SESSION Applying MM4H Approaches to Product Markets
More informationInnovative Approaches to Saving Patients Money on Prescription Drug Costs
Innovative Approaches to Saving Patients Money on Prescription Drug Costs April 2018 1 Innovative Approaches to Saving Patients Money on Prescription Drug Costs Executive Summary As prescription drug prices
More informationUsing Your Prescription. Drug Program. Answers to important questions about retail pharmacy and mail order purchasing
Using Your Prescription Drug Program Answers to important questions about retail pharmacy and mail order purchasing Welcome! We know you re going to enjoy the many advantages of your prescription drug
More informationIntroduction to the Generic Drug Supply Chain and Key Considerations for Policymakers
Association for Accessible Medicines Introduction to the Generic Drug Supply Chain and Key Considerations for Policymakers Key Takeaways Generic drugs play an important role in the U.S. health care system,
More informationPharmaceutical Trademarks
Published by Pharmaceutical Trademarks 2012 Hungary Contributing firm Third Edition Hungary Contributing firm Author Georgina Busku Selection, clearance and registration The following trademarks may enjoy
More informationFrom Volume to Value: Using payer insights to increase sales effectiveness
From Volume to Value: Using payer insights to increase sales effectiveness by Anita Burrell The collective will of the provider community has moved to acquiescence to the payer will controlling costs and
More informationItalian post-marketing registries
Italian post-marketing registries Entela Xoxi Budapest Conference - October 16, 2012 Public Declaration of transparency/interests* The view and opinions expressed in the following PowerPoint slides are
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)51 DAF/COMP/GF/WD(2014)51 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 14-Feb-2014 English
More informationOntario s Narcotics Strategy
Ontario Public Drug Programs Division Ontario s Narcotics Strategy Notice from the Executive Officer: Implementation of the Narcotics Monitoring System The Ministry of Health and Long-Term Care ( ministry
More informationHow can the controlled drug procedure become more efficient? Emma has suggested using: An electronic spreadsheet to record the controlled drugs register, as mathematical errors were a problem in her current
More informationUPS Healthcare Supply Chain Vital Signs
UPS Study Executive September 2017 START 2017 UPS Survey 2017 United Parcel Service of America, Inc. 1 An industry growing more complex: managing competition, compliance and costs Pharmacies are grappling
More informationYASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA.
YASHAJIT SAHA & ABHISHEK SHARMA, SUBJECT MATTER EXPERTS, RESEARCH & ANALYTICS ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN PHARMA wns wns ADVANCED ANALYTICS: A REMEDY FOR COMMERCIAL SUCCESS IN
More informationMaximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS
Maximizing Market Access: THE 5 MOST CRITICAL QUESTIONS TO ASK WHEN LAUNCHING A SPECIALTY DRUGS by Jan Nielsen, division president, Access & Patient Support Are You Asking the Right Questions? We ve all
More informationCalculations. Pricing. Pharmacy Technician Training Systems Passassured, LLC
Calculations Pricing Pharmacy Technician Training Systems Passassured, LLC p2 Calculations, Pricing PassAssured's Pharmacy Technician Training Program Calculations Pricing Click Here for Glossary Index!
More informationLessons from AMFm how this informs RDT introduction in Private Sector. Vivian N.A. Aubyn NMCP Ghana
Lessons from AMFm how this informs RDT introduction in Private Sector Vivian N.A. Aubyn NMCP Ghana AMFm Objectives and Strategy Objectives Increase access to ACTs Fight resistance by driving artemisinin
More informationAMCP Webinar Series. Education for Health Care Providers The New Frontier for Biosimilars. How to Ask A Question 8/24/2016.
AMCP Webinar Series Education for Health Care Providers The New Frontier for Biosimilars August 24, 2016 How to Ask A Question Type your question in the Questions area 1 Education for Health Care Providers
More informationPOSITION DESCRIPTION
POSITION DESCRIPTION Position Title: Reports to: SENIOR / THERAPEUTIC GROUP MANAGER (TGM) TEAM LEADER, PHARMACEUTICAL FUNDING Date: 1 November 2014 PURPOSE OF THE POSITION The primary purpose of this role
More informationPharmaco-Epidemiological Studies. A French experience
Pharmaco-Epidemiological Studies A French experience CVZ, Diemen, December 1 st, 2006 Hubert MECHIN, MD CEO MAPI-NAXIS Lyon, France Vocabulary Pharmaco epidemiological studies Observational studies Post-authorization
More informationTransitioning to Express Scripts Frequently Asked Questions
Transitioning to Express Scripts Frequently Asked Questions CONTENTS GENERAL INFORMATION... 1 WELCOME MATERIALS... 1 PHARMACY COVERAGE... 2 REFILL TRANSFER INFORMATION... 3 HOME DELIVERY... 4 SPECIALTY
More informationFirst Plenary Session CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE. Jean-Luc Harousseau, MD
First Plenary Session Speaker CONVERGING OR DIVERGING MODELS OF HTA IN EUROPE Jean-Luc Harousseau, MD President and Chairman of the Board Haute Autorité de Santé (HAS) Saint-Denis La Plaine, France HTA
More informationThe compassionate use of medicinal products. An example: the French ATU system. 0ff label use in France
0 The compassionate use of medicinal products. An example: the French ATU system 0ff label use in France C. Bélorgey Head of Department of evaluation of Clinical Trials and medicinal products of special
More informationIndustry Overview & Strategic Growth Framework
A Pharmacy Innovation Company Industry Overview & Strategic Growth Framework Larry Merlo President & Chief Executive Officer Agenda Rapidly-changing health care environment Uniquely positioned to drive
More informationApproach & Methodology of the Study Objective & Scope 3. Methodology 3. Secondary Research & Research Tool Development 3. Primary Research 3
Contents Approach & Methodology of the Study... 3 Objective & Scope 3 Methodology 3 Secondary Research & Research Tool Development 3 Primary Research 3 Demographic Characteristics of Consumer Respondents
More informationTransitioning to Express Scripts
Transitioning to Express Scripts Welcome to Express Scripts. We re pleased to announce that, beginning January 1, 2017 the Michigan Tech prescription benefit will be managed by Express Scripts. Express
More informationACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN 6/26/2018. Presentation to UN 2018 Public Service Forum. Richard Bergström External Lead Pharma
ACCOUNTABILITY AND TRANSPARENCY IN PHARMA SUPPLY CHAIN Presentation to UN 2018 Public Service Forum Richard Bergström External Lead Pharma Enabling trust 1 SICPA: GLOBAL ROLE Protection of 85+% world currency
More informationExecutive Summary. Variation in per capita expenditure on pharmaceuticals is relatively low across OECD countries...
ISBN 978-92-64-04414-2 Pharmaceutical Pricing Policies in a Global Market OECD 2008 Executive Summary Variation in per capita expenditure on pharmaceuticals is relatively low across OECD countries... The
More informationImplementation of Pharmaceutical Policy Reform. Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank
Implementation of Pharmaceutical Policy Reform Andreas Seiter Senior Health Specialist Access to Essential Medicine The World Bank Sector issues Critical sector for health outcomes Characterized by market
More informationAmgen GLOBAL CORPORATE COMPLIANCE POLICY
1. Scope Applicable to all Amgen Inc. and subsidiary or affiliated company staff members, consultants, contract workers, secondees and temporary staff worldwide ( Covered Persons ). Consultants, contract
More informationPolicy principles for a competitive healthcare environment
Policy principles for a competitive healthcare environment Pharmaceutical Research and Development Industry Malta Association (PRIMA) PRIMA is an affiliate of the European Federation of Pharmaceutical
More informationPrescription Drug Pricing Poll, conducted for Prescription Justice by Zogby Analytics *Margin of error +/- 3.1
Prescription Drug Pricing Poll, conducted for Prescription Justice by Zogby Analytics *Margin of error +/- 3.1 1. Question: President Donald Trump recently told reporters that pharmaceutical companies
More informationADVANCING THE SINGLE MARKET FOR MEDICINES GIRP Position Paper
ADVANCING THE SINGLE MARKET FOR MEDICINES GIRP Position Paper 1. The Single Market The single internal European market was one of the primary stated purposes of the 1957 Treaty of Rome. The arrangements
More informationPHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN
PHARMACEUTICAL PRICING & REIMBURSEMENT SYSTEM IN SPAIN PPRI Conference 29-30 September 2011, Vienna Piedad Ferré Pharmaceutical offer in Spain some features High coverage and rapid accessibility Pharmaceutical
More informationPharmaceutical pricing, i reimbursement, Europe: an overview (I) Elias Mossialos and Reinhard Busse
Pharmaceutical pricing, i reimbursement, HTA and cost containment measures in Europe: an overview (I) Elias Mossialos and Reinhard Busse Policy issues in pharmaceutical markets Structure of the pharmaceutical
More informationBRITISH GENERIC MANUFACTURERS ASSOCIATION
BRITISH GENERIC MANUFACTURERS ASSOCIATION Response by the British Generic Manufacturers Association (BGMA) to the Department of Health Consultation on Amendments to the Statutory Scheme to Control the
More informationCerpassRx Member Handbook
CerpassRx Member Handbook Welcome CerpassRx is pleased to administer your prescription benefit plan. About Us CerpassRx is an innovative Pharmacy Benefit Administrator that offers access to pharmacies
More informationSummary of Medicines Plan
Summary of Medicines Plan Ministry of Public Health, Welfare and Sport Summary of Medicines Plan 1 Content Introduction 4 1 Accessibility of innovative medicines 5 Go to action 2 Tackle the high price
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationUniform licensing by EMA followed by patchwork implementation in the European Union when it comes to implementation
Vs15i17 2nd MENA Regulatory conference on Bioequivalence, Biowaivers, Bioanalysis, Dissolution and Biosimilars Amman, 17 September 2015 Uniform licensing by EMA followed by patchwork implementation in
More informationNordic Instructions for Nordic Article Numbers (Vnrs) Supplementary information Norway. 1. The flow of article information
1 Nordic Instructions for Nordic Article Numbers (s) Supplementary information Norway This document presents an overview on the handling of s (Varenummer/article number) and information carried by the
More informationHow to treat more patients and make money in emerging markets
1 How to treat more patients and make money in emerging markets AUTHOR Raja Shankar RShankar@imscg.com People buy innovative products in emerging markets. Millions of Brazilians, Russians, Indians, Chinese,
More informationFREQUENTLY ASKED QUESTIONS
CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find
More informationWendy Poirier, Director of Towers Watsons Canadian Health & Group Benefits Practice talks about the Canadian Rx Coalition
EXCLUSIVE INTERVIEW: Wendy Poirier, Director of Towers Watsons Canadian Health & Group Benefits Practice talks about the Canadian Rx Coalition Today I am pleased to interview Wendy Poirier Director of
More informationImportant Prescription Benefit Information
Important Prescription Benefit Information Prepared Exclusively for: Wichita Center for Graduate Medical Education HDHP Plan medtrakrx.com Welcome to MedTrakRx Dear Member: This booklet contains important
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2018 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationMEDICINES CONTROL COUNCIL
Licence to act as a Wholesaler or Distributor MEDICINES CONTROL COUNCIL GUIDELINES FOR LICENCE TO ACT AS A WHOLESALER or DISTRIBUTOR This guideline is intended to provide recommendations to applicants
More informationPrescription Medicines: Costs in Context
Prescription Medicines: Costs in Context 2017 We are in a new era of medicine where breakthrough science is transforming care with innovative treatment approaches... Then Now Medicines made of chemical
More informationTeva operates in both the generics and branded medicines markets, with generics being our primary area of focus.
Opening statement by Ms Sandra Gannon, General Manager, Teva Pharmaceuticals Ireland, to the Oireachtas Joint Committee on Health and Children, Thursday 5 March 2015 Good morning. Chairman, Committee and
More informationLancet article* on medicine prices, availability and affordability Questions and Answers, January 2009
Lancet article* on medicine prices, availability and affordability Questions and Answers, January 2009 *Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, affordability in
More informationThe need for generic policies as part of health reform
The need for generic policies as part of health reform Richard Laing EMP/WHO for PPRI Conference Vienna September 30 th 2011 The US Generics Market reaches $107.5bn with growth four times higher than total
More informationTechnical Briefing Seminar - Pricing Policies
Technical Briefing Seminar - Pricing Policies Geneva, Switzerland 10 October 2017 Andrew Rintoul Scientist Innovation Access and Use Essential Medicines and Health Products Outline Access to Medicines
More informationFigure 1: Prevalence of On-Site Clinics Do you currently offer an on-site health clinic for your employees at one or more of your locations?
March 2011 Due to interest from members relating to healthy workplace initiatives, WorldatWork conducted a snapshot survey to quickly gauge current practices regarding the prevalence and design of on-site
More informationDrug Reimportation: Learning from the experience in Europe
1 24/02/2004 Drug Reimportation: Learning from the experience in Europe National Medicare Prescription Drug Congress Washington DC 27 February 2004 2 24/02/2004 Contents Differences between the US and
More informationLocal Authority and Provider welcome pack
Information Services provided by Business Services Authority Local Authority and Provider welcome pack Local Authority and Provider welcome pack (V1.5) 08.2016 Contents Introduction... 3 Setting up an
More informationHow Does Your Consumer-Driven Health Plan Work?
Veritas HRA News How Does Your Consumer-Driven Health Plan Work? 1. Health Reimbursement Arrangement (HRA) Your employer is funding an annual dollar amount into your Health Reimbursement Arrangement (HRA)
More informationOpen Enrollment 2014 FAQs Express Script Prescription Drug Plan
Open Enrollment 2014 FAQs Express Script Prescription Drug Plan Q. What is a co-payment or coinsurance? A. A co-payment is typically a flat dollar amount, and coinsurance is a percentage of a medication
More informationA New Standard Of Providing Subjects Unblinded Medication And Supplies
A New Standard Of Providing Subjects Unblinded Medication And Supplies Tom Heck May 2017 Introduction Tom Heck President RxSolutions, Inc. 24 years in Pharmaceuticals Integral or in leadership at six specialty
More informationStatement. For. United States Senate Committee on Finance. June 8, :45 a.m.
Statement of The National Association of Chain Drug Stores For United States Senate Committee on Finance On The President s Fiscal Year 2018 Budget 9:45 a.m. 215 Dirksen Senate Office Building National
More informationExpress Scripts Frequently Asked Questions
Express Scripts Frequently Asked Questions CONTENTS GENERAL INFORMATION... 1 WELCOME MATERIALS... 1 PHARMACY COVERAGE... 2 HOME DELIVERY... 3 SPECIALTY MEDICATIONS... 4 PRIOR AUTHORIZATONS... 4 DRUG QUANTITY
More informationCase Commentary. Innovative marketing strategies after patent expiry
Innovative marketing strategies after patent expiry Pierre Chandon writes: In 2003, what can we learn from what happened to Clamoxyl in France in 1996? The Clamoxyl story shows that pharmaceutical brands
More informationChapter 2 E-Marketplaces: Structure, Mechanisms, Economics, and Impacts
Electronic Commerce 2006 Chapter 2 E-Marketplaces: Structure, Mechanisms, Economics, and Impacts True-False Questions 1. A central role of markets in an economy is to facilitate the exchange of information,
More informationMaintaining the blind for clinical trials in Pharmacy
York Foundation Trust R&D Unit SOP Pharm/S89 Maintaining the blind for clinical trials in Pharmacy IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO ENSURE THAT THE CORRECT VERSION IS BEING USED All
More informationThe transition to OptumRx is designed to help us better serve your employees and help improve their overall experience:
September 27, 2013 RE: Pharmacy Benefit Transition Plan for Oxford Clients Dear Valued Oxford Client, We are pleased to confirm that, effective Oct. 1, 2013, your pharmacy benefit services are being administered
More informationPolicies Approved by the 2018 ASHP House of Delegates
House of Delegates Policies Approved by the 2018 ASHP House of Delegates 1801 Unit Dose Packaging Availability To advocate that pharmaceutical manufacturers provide all medications used in health systems
More informationNordic Instructions for Nordic Article Numbers (Vnrs) Supplementary information Norway. 1. The flow of article information
1 Nordic Instructions for Nordic Article Numbers (s) Supplementary information Norway This document presents an overview on the handling of s (Varenummer/article number) and information carried by the
More informationNew WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research
New WHO Report: Access to new medicines in Europe: Technical review of policy initiatives and opportunities for collaboration and research Hanne Bak Pedersen Programme Manager Health Technologies and Pharmaceuticals
More informationInterchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance
Interchangeability: What is Next? Analysis of the concept & of the FDA Draft Guidance Hillel Cohen, Executive Director of Scientific Affairs Leading on Biosimilars: The 2017 AAM Biosimilars Council Conference
More informationKansas Pharmacy Act Amendments; Filling and Refilling Prescriptions; Biological Products; Senate Sub. for HB 2055
Kansas Pharmacy Act Amendments; Filling and Refilling Prescriptions; Biological Products; Senate Sub. for HB 2055 (Act). Senate Sub. for HB 2055 makes several amendments to the Kansas Pharmacy Act The
More informationDelegation and Technician Training. Kenneth W. Schafermeyer, PhD Senior Fellow Institute for the Advancement of Community Pharmacy Fenton, Missouri
Delegation and Technician Training Kenneth W. Schafermeyer, PhD Senior Fellow Institute for the Advancement of Community Pharmacy Fenton, Missouri Learning Objectives Describe how well-trained pharmacy
More informationD&E DATOS Y ESTRATEGIAS PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES
PHYSICIANS PERCEPTIONS ABOUT THE PROMOTIONAL PRESSURE BY NATIONAL AND MULTINATIONAL PHARMACEUTICAL COMPANIES FOR THE PERIOD 2005-2013 Survey 2013 1 CURRENT SCENARIO IN ARGENTINA The pharmaceutical industry
More informationINTERNATIONAL DIFFERENCES IN DRUG PRICES
Annu. Rev. Public Health 2004. 25:475 95 doi: 10.1146/annurev.publhealth.25.101802.123042 Copyright c 2004 by Annual Reviews. All rights reserved INTERNATIONAL DIFFERENCES IN DRUG PRICES Judith L. Wagner
More informationWhat To Do or Not To Do? Utility of Medication Traceability to the Patient
What To Do or Not To Do? Utility of Medication Traceability to the Patient Melsen Kwong, Pharm.D. Associate Director Department of Pharmacy Services Cedars-Sinai Medical Center, Los Angeles, CA, USA Objectives
More informationSUBSTANCE ABUSE POLICY
SUBSTANCE ABUSE POLICY The Company has a vital interest in the health and welfare of its employees. The misuse and abuse of alcohol and drugs by employees pose serious threats to the safety and health
More informationPharmacy Service Improvement at CVS
Pharmacy Service Improvement at CVS Business Seminar Case Study Bethany Odom, Katie Tewell, Kelly Snider, Brad Lowe Table of Contents Introduction.3 Day-to-Day Operations Diagram.4 Drop Off..5 Data Entry
More informationProject Destiny Summary
Project Destiny Summary The American Pharmacists Association (APhA), the National Association of Chain Drug Stores (NACDS), and the National Community Pharmacists Association (NCPA) have joined together
More informationWhy is Healthcare Stuck in Reporting?
Roundtable Discussion Why is Healthcare Stuck in Reporting? April 2013 Moderated by: Bryan Engle should be directed to members@. Overview Understanding and obtaining the benefits of advanced analytics
More informationTestimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC
Testimony of Molly Ventrelli Vice President, Regulatory Affairs Fresenius Kabi USA, LLC U.S. House of Representatives Energy and Commerce Committee Subcommittee on Health Subcommittee January 30, 2018
More informationSeptember 9, Mr. Mark A. Thierer Chief Executive Officer OptumRx 1600 McConnor Parkway Schaumburg, IL
September 9, 2016 Mr. Mark A. Thierer Chief Executive Officer OptumRx 1600 McConnor Parkway Schaumburg, IL 60173-6801 Via email: mark.thierer@optum.com Dear Mr. Thierer: It has recently come to our attention
More informationMARKET ACCESS & PUBLIC AFFAIRS MANAGER BELUX
MARKET ACCESS & PUBLIC AFFAIRS MANAGER BELUX Sofie Paeps Valerie Van Sannen Senior Executive Search Consultant Executive Search Consultant 0032.478.93.15.11 0032.485.97.52.32 sofie.paeps@hronegroup.com
More informationCase Study 2: France. 2.1 Context
Case Study 2: France 2.1 Context The French White Certificates have been in place since July 2006 and arose out of the new French energy policy law passed in July 2005. It places an obligation on suppliers
More informationTransportation. Researching an Automobile What should I look for?
Transportation Researching an Automobile What should I look for? Transportation Part of everyone s life 15 20% of an individual s budget Automobile is the 2 nd most expensive purchase, only after a home
More informationA Paper Prepared for ABRACE by Ashley C. Brown, June 10, Advice on the Brazilian Natural Gas Market
A Paper Prepared for ABRACE by Ashley C. Brown, June 10, 2014 Advice on the Brazilian Natural Gas Market The natural gas market in Brazil is largely dysfunctional and constitutes a major barrier to the
More informationPolicy Position. Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs)
Pharmacy-mediated interchangeability for Similar Biotherapeutic Products (SBPs) Geneva, April 2016 Appropriate use of biotherapeutics including SBPs - SBPs, also known as biosimilars, are developed to
More informationObjective. Rationale. Subsidised spectacle schemes across Australia
Principles for nationally consistent subsidised spectacle schemes for Aboriginal and Torres Strait Islander people - Recommended implementation standards Objective These principles and recommended standards
More informationEnterprise Systems in Healthcare - Blessing or Curse?
Enterprise Systems in Healthcare - Blessing or Curse? Research topics that interest me... Three agendas: n Evolution and assessment of information systems Evolution of information systems Business value
More informationBiopharma in the coming era of connected health
14 Health-care focus: Perspective Celia Johnson Biopharma in the coming era of connected health Disruptive technologies are already reshaping the industry. Here s how executives can meet the resulting
More informationAfter studying this chapter you will be able to
3 Demand and Supply After studying this chapter you will be able to Describe a competitive market and think about a price as an opportunity cost Explain the influences on demand Explain the influences
More informationDecember Thirty-One
December Thirty-One 2 0 1 8 Seema Verma, Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services P.O. Box 8013 Baltimore, MD 21244-8013 Re: [CMS-5528-ANPRM; RIN 0938-AT91]
More informationCONTINUING MEDICAL AND DENTAL EDUCATION POLICY. Date ratified: 3 September Date issued: 3 September 2007
CONTINUING MEDICAL AND DENTAL EDUCATION POLICY Version: 4 Ratified by (name of Committee): JLNC Date ratified: Date issued: Expiry date: 31 December 2012 (Document is not valid after this date) Review
More informationBi Regional Consultation on Good Governance
Pharmaceutical Services Ministry of Health Malaysia GGM PROGRAMME IN MALAYSIA WHO Collaborating Centre For Regulatory Control of Pharmaceuticals Bi Regional Consultation on Good Governance 9 th November
More informationReal World Evidence, Digital Health and Market Access
Real World Evidence, Digital Health and Market Access Dr. Kyle E. Dolbow Oncology Market Access Market Access It s going to be a fact of life that we have to accept a slower uptake, Mr. Jimenez told the
More informationCharting a Steady Course
2 0 1 6 BENEFITS STRATEGY & BENCHMARKING SURVEY INDUSTRY ADDENDUM ENERGY Charting a Steady Course Survey Overview Gallagher s 2016 Benefits Strategy & Benchmarking Survey provides insights into how benefit
More informationKey Takeaways from the Winter 340B Coalition Conference
Key Takeaways from the Winter 340B Coalition Conference Kristin Fox-Smith, MPA Douglas E. Miller, PharmD Tony Zappa, PharmD, MBA February 25, 2016 1 Visante Structure Founded in 1999 to provide pharmacy-related
More informationpan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation
pan-canadian Oncology Drug Review Patient Advocacy Group Feedback on a pcodr Expert Review Committee Initial Recommendation Ixazomib (Ninlaro) for Multiple Myeloma Myeloma Canada June 29, 2017 1. Feedback
More informationRecommendations for Strengthening the Investigator Site Community
Recommendations for Strengthening the Investigator Site Community October 2017 CTTI MISSION: To develop and drive adoption of practices that will increase the quality and efficiency of clinical trials
More informationBtwentyfour services. (English version 2010)
Btwentyfour services (English version 2010) Enabled EDI The fast track to communicating business information Sometimes, situations arise where you need to instantly fulfill customer requirements and communicate
More informationIT and Competitive Advantages LEARNING OUTCOMES 1/26/2016. January 27, Understand each of the five forces in Porter s Five Forces Model
IT and Competitive Advantages January 27, 2016 LEARNING OUTCOMES Understand each of the five forces in Porter s Five Forces Model Determine kind of IT that help deal with the 5 forces and gain competitive
More informationUnderstanding the anti-malarial market Carrying out the survey: Lessons learnt
Understanding the anti-malarial market Carrying out the survey: Lessons learnt Survey team: Area Supervisors, Data Collectors and Data entrants Aziz Maija, Survey manager Collection of relevant information
More informationPacking and Shipping Tech. Job Title: Packing and Shipping Tech. Education: High School. Location: divvydose, Rock Island, IL
Packing and Shipping Tech Job Title: Packing and Shipping Tech Education: High School Location: divvydose, Rock Island, IL Career Level: Entry Level Job Type: Full-time FLSA Status: Non-Exempt Company
More informationPharmaceutical Marketing. lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais
Pharmaceutical Marketing lecture Two Microenvironment Environment Lecturer: Enas Abu-Qudais Marketing Environment There are various factors/ forces, that directly or indirectly influence the organizations
More information